Literature DB >> 25970228

Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.

Yanling Wang1, Xiaomin Zhang, Yuchao Zhang, Yuming Zhu, Chunping Yuan, Bin Qi, Wei Zhang, Dongmiao Wang, Xu Ding, Heming Wu, Jie Cheng.   

Abstract

Abnormal glucose metabolism mediated by pyruvate kinase M2 (PKM2) fuels cancer overgrowth and propagation. However, its expression and oncogenic roles in in oral squamous cell carcinoma (OSCC) remains incompletely known. Here, we aimed to investigate the expression of PKM2, its prognostic values and oncogenic functions using 7,12-dimethyl-1,2-bezan-tracene (DMBA)-induced hamster buccal pouch SCC model, primary OSCC specimens as well as in vitro cellular assays. We found that in DMBA-induced OSCC model, negative PKM2 expression was commonly observed in normal epithelial, while more PKM2 abundance was detected in hyperplasia, dysplasia and SCC. Overexpression of PKM2 in a major fraction of OSCC significantly associated with tumor size (P = 0.027), cervical node metastasis (P = 0.004) and clinical stages (P = 0.000). Patients with increased PKM2 had remarkably reduced overall and disease-free survival. Multivariate survival analysis further revealed that PKM served as a critical independent prognostic factor for patients' overall survival. Furthermore, impaired cell proliferation and migration, and reduced apoptosis were detected upon PKM2 knockdown in HN4 and HN12 cells. Taken together, our findings reveal that PKM2 is critically involved in OSCC initiation and progression probably by promoting cell proliferation and migration as well as reducing apoptosis. Its overexpression correlates with aggressive clinicopathological features and poor patients' outcome.

Entities:  

Keywords:  PKM2; Warburg effect; aerobic glycolysis; oral squamous cell carcinoma; pyruvate kinase M2

Mesh:

Substances:

Year:  2015        PMID: 25970228      PMCID: PMC4622565          DOI: 10.1080/15384047.2015.1030551

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  26 in total

1.  Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer.

Authors:  Alexander D Rapidis; Patrick Gullane; John D Langdon; Jean Louis Lefebvre; Crispian Scully; Jatin P Shah
Journal:  Oral Oncol       Date:  2009 Apr-May       Impact factor: 5.337

Review 2.  Glycolysis inhibition for anticancer treatment.

Authors:  H Pelicano; D S Martin; R-H Xu; P Huang
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

3.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

Authors:  B Altenberg; K O Greulich
Journal:  Genomics       Date:  2004-12       Impact factor: 5.736

4.  JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism.

Authors:  Hung-Jung Wang; Ya-Ju Hsieh; Wen-Chi Cheng; Chun-Pu Lin; Yu-shan Lin; So-Fang Yang; Chung-Ching Chen; Yoshihiro Izumiya; Jau-Song Yu; Hsing-Jien Kung; Wen-Ching Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

5.  Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling.

Authors:  Thian-Sze Wong; Xiao-Bing Liu; Ambrose Chung-Wai Ho; Anthony Po-Wing Yuen; Raymond Wai-Man Ng; William Ignace Wei
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

6.  Pharmacologic activation of PKM2 slows lung tumor xenograft growth.

Authors:  K Mark Parnell; Jason M Foulks; Rebecca N Nix; Adrianne Clifford; Jeremy Bullough; Bai Luo; Anna Senina; David Vollmer; Jihua Liu; Virgil McCarthy; Yong Xu; Michael Saunders; Xiao-Hui Liu; Scott Pearce; Kevin Wright; Marc O'Reilly; Michael V McCullar; Koc-Kan Ho; Steven B Kanner
Journal:  Mol Cancer Ther       Date:  2013-05-29       Impact factor: 6.261

7.  Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.

Authors:  Zhongwu Li; Yanling Wang; Chunping Yuan; Yumin Zhu; Jing Qiu; Wei Zhang; Bing Qi; Heming Wu; Jinhai Ye; Hongbing Jiang; Jianrong Yang; Jie Cheng
Journal:  Lab Invest       Date:  2014-10-06       Impact factor: 5.662

Review 8.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

9.  The value of expression of M2-PK and VEGF in patients with advanced gastric cancer.

Authors:  Lanning Yin; Xiang Wang; Changjiang Luo; Haipeng Liu; Ling Zhang; Hong Zhang; Youcheng Zhang
Journal:  Cell Biochem Biophys       Date:  2013       Impact factor: 2.194

10.  The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.

Authors:  Zhongwu Li; Yanling Wang; Jing Qiu; Qiang Li; Chunping Yuan; Wei Zhang; Dongmiao Wang; Jinhai Ye; Hongbin Jiang; Jianrong Yang; Jie Cheng
Journal:  Oncotarget       Date:  2013-12
View more
  16 in total

Review 1.  Drugging cancer metabolism: Expectations vs. reality.

Authors:  David C Montrose; Lorenzo Galluzzi
Journal:  Int Rev Cell Mol Biol       Date:  2019-07-29       Impact factor: 6.813

2.  Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome.

Authors:  Goran Hamid Mohammad; S W M Olde Damink; Massimo Malago; Dipok Kumar Dhar; Stephen P Pereira
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

3.  Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies.

Authors:  Jiayuan Wu; Liren Hu; Manyu Chen; Wenjun Cao; Haicong Chen; Taiping He
Journal:  Onco Targets Ther       Date:  2016-07-14       Impact factor: 4.147

4.  Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis.

Authors:  Haiyan Zhu; Hui Luo; Xuejie Zhu; Xiaoli Hu; Lihong Zheng; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-01-03

5.  PKM2 enhances cancer invasion via ETS-1-dependent induction of matrix metalloproteinase in oral squamous cell carcinoma cells.

Authors:  Young-Jin Park; Jue Young Kim; Doo Young Lee; Xianglan Zhang; Shadavlonjid Bazarsad; Won-Yoon Chung; Jin Kim
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

6.  Tumor M2-PK: A novel urine marker of bladder cancer.

Authors:  Weiya Liu; Benjamin L Woolbright; Karim Pirani; Ryan Didde; Erika Abbott; Gaurav Kaushik; Paige Martin; Jill Hamilton-Reeves; John A Taylor; Jeffrey M Holzbeierlein; Shrikant Anant; Eugene K Lee
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

7.  Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis.

Authors:  Ming Li; Feng Gao; Qing Zhao; Huilan Zuo; Wenbin Liu; Wei Li
Journal:  Cell Death Dis       Date:  2020-05-18       Impact factor: 8.469

8.  Extracellular vesicles secreted by highly metastatic clonal variants of osteosarcoma preferentially localize to the lungs and induce metastatic behaviour in poorly metastatic clones.

Authors:  Rebecca Macklin; Haolu Wang; Dorothy Loo; Sally Martin; Andrew Cumming; Na Cai; Rebecca Lane; Natalia Saenz Ponce; Eleni Topkas; Kerry Inder; Nicholas A Saunders; Liliana Endo-Munoz
Journal:  Oncotarget       Date:  2016-07-12

Review 9.  Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.

Authors:  Ming-Chuan Hsu; Wen-Chun Hung
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  The Multifarious Functions of Pyruvate Kinase M2 in Oral Cancer Cells.

Authors:  Miyako Kurihara-Shimomura; Tomonori Sasahira; Chie Nakashima; Hiroki Kuniyasu; Hiroyuki Shimomura; Tadaaki Kirita
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.